William Zamboni, PharmD, PhD
One of the first scientists recruited with help from the UCRF, Zamboni directs a drug development and clinical pharmacology lab focusing on the translational development of drugs, anticancer agents, and nanoparticles.
Dr. William Zamboni was one of the first scientists recruited with help from the University Cancer Research Fund. Zamboni, who came to UNC from the University of Pittsburgh, is an associate professor in the School of Pharmacy’s Division of Pharmacotherapy and Experimental Therapeutics and a member of UNC Lineberger. He is also a member of the School of Pharmacy’s Institute for Pharmacogenomics and the Carolina Center of Cancer Nanotechnology Excellence.
Zamboni is directing the TOND2I (Translational Oncology and Nanoparticle Drug Development Initiative) Lab – a drug development and clinical pharmacology lab focusing on the translational development of drugs, anticancer agents, and nanoparticles. The lab has the capacity to support all pharmacologic studies required in translational drug development and is already supporting multiple pre-clinical and clinical trials.
He has also established a Good Laboratory Practice (GLP) Analytical Facility at UNC, one of a few such labs in an academic center in the entire country. This facility will provide a unique and globally impacting resource that will foster and accelerate internal and external drug development and provide training in translational drug development and clinical pharmacology. The GLP Facility is targeted to open in September of 2009.
Zamboni, along with Dr. Paola Gehrig, Assistant Professor in the Division of Gynecologic Oncology, are conducting a clinical trial that opened in June of 2009 titled “Doxil + TSC Phenotypic Imaging in Patients with Ovarian Cancer.” The proposal for this trial received an University Cancer Research Fund Innovation Award in June 2008.
The ability to perform initial preclinical pharmacologic studies of investigational agents discovered at UNC in a GLP analytical laboratory can significantly accelerate the development of these agents and will be used as a tool to recruit investigational agents developed by the National Institutes of Health, the National Cancer Institute, and pharmaceutical companies to UNC. This facility makes UNC more competitive when applying for grants from federal agencies and provides the best environment in which to develop new therapies for UNC Lineberger’s Early Phase Clinical Trials Program.
Read more about Dr. Zamboni in the Carolina Alumni Review